| First Author | Caddy SL | Year | 2021 |
| Journal | EMBO J | Volume | 40 |
| Issue | 5 | Pages | e106228 |
| PubMed ID | 33258165 | Mgi Jnum | J:303981 |
| Mgi Id | MGI:6510449 | Doi | 10.15252/embj.2020106228 |
| Citation | Caddy SL, et al. (2021) Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity. EMBO J 40(5):e106228 |
| abstractText | Nucleoprotein (N) is an immunodominant antigen in many enveloped virus infections. While the diagnostic value of anti-N antibodies is clear, their role in immunity is not. This is because while they are non-neutralising, they somehow clear infection by coronavirus, influenza and LCMV in vivo. Here, we show that anti-N immune protection is mediated by the cytosolic Fc receptor and E3 ubiquitin ligase TRIM21. Exploiting LCMV as a model system, we demonstrate that TRIM21 uses anti-N antibodies to target N for cytosolic degradation and generate cytotoxic T cells (CTLs) against N peptide. These CTLs rapidly eliminate N-peptide-displaying cells and drive efficient viral clearance. These results reveal a new mechanism of immune synergy between antibodies and T cells and highlights N as an important vaccine target. |
